EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	107.63M +13.5%
Revenue (ttm)	51.56M +2.7%
Net Income	2.12M -66.0%
EPS	0.00 -65.8%
Shares Out	430.50M
PE Ratio	53.20
Forward PE	15.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,134
Average Volume	174,812
Open	26.50
Previous Close	26.30
Day's Range	25.00 - 26.50
52-Week Range	19.00 - 32.00
Beta	0.53
RSI	48.05
Earnings Date	Jun 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 297
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.